EMKinetics has begun the TranStim transdermal neuromodulation system trial in patients suffering from urge incontinence and overactive bladder.
TranStim therapy is based on the fact that posterior tibial nerve stimulation (PTNS) can generate a clinically significant improvement in patients suffering from urge incontinence and an overactive bladder.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
EMKinetics co-founder Marshall Stoller said the TranStim system has the potential to safely and consistently provide transdermal PTNS therapy.
The initiation of the pivotal trial follows the closing of EMKinetics’ Series C financing of $8m, led by Allergan.
Following the completion of the study, the company plans to submit data for CE mark approval.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
